FSD-Pharma

Prismic Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on developing novel prescription medical foods for the clinical dietary management of the metabolic processes associated with disorders commonly seen in the aging “baby boomer” population. These include disorders of the central nervous system (CNS), as well as conditions where inflammation is an underlying or significant cause of the disorder.. The company's initial product candidates are focused on the use of a highly purified form of Omega-3 fatty acids in combination with other molecules for the treatment of CNS disorders, and are protected by a series of issued U.S. and foreign composition and use patents.

SciSparc is a clinical-stage pharmaceutical company specializing in developing cannabinoid-based drugs. The company's portfolio includes several drug development programs, notably THX-110, which has completed a Phase IIa clinical trial for treating Tourette syndrome and obstructive sleep apnea, and THX-160, which is in preliminary studies for managing acute and chronic pain. Additionally, THX-210 is under development for autism spectrum disorder and epilepsy. SciSparc has partnered with The University of Calgary to explore the analgesic effects of its proprietary CB2R agonist drug candidate, THX-160. The firm also focuses on repurposing FDA-approved synthetic cannabinoids, with initiatives like Joint Pharma, which is developing THX-TS01 for Tourette syndrome, and BrainBright Pharma, which is working on THX-ULD01 aimed at addressing mild cognitive impairments. Founded in 2004 and headquartered in Givatayim, Israel, SciSparc aims to enhance its portfolio through innovative research and development in cannabinoid therapies.